Literature DB >> 33095300

Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection.

Patrick Carius1,2, Justus C Horstmann1,2, Cristiane de Souza Carvalho-Wodarz1,2, Claus-Michael Lehr3,4.   

Abstract

Lung diseases have increasingly attracted interest in the past years. The all-known fear of failing treatments against severe pulmonary infections and plans of the pharmaceutical industry to limit research on anti-infectives to a minimum due to cost reasons makes infections of the lung nowadays a "hot topic." Inhalable antibiotics show promising efficacy while limiting adverse systemic effects to a minimum. Moreover, in times of increased life expectancy in developed countries, the treatment of chronic maladies implicating inflammatory diseases, like bronchial asthma or chronic obstructive pulmonary disease, becomes more and more exigent and still lacks proper treatment.In this chapter, we address in vitro models as well as necessary in vivo models to help develop new drugs for the treatment of various severe pulmonary diseases with a strong focus on infectious diseases. By first presenting the essential hands-on techniques for the setup of in vitro models, we intend to combine these with already successful and interesting model approaches to serve as some guideline for the development of future models. The overall goal is to maximize time and cost-efficacy and to minimize attrition as well as animal trials when developing novel anti-infective therapeutics.

Entities:  

Keywords:  Air-blood barrier; Air-liquid interface (ALI); Biofilm; Cystic fibrosis; Deposition; Mycobacterium tuberculosis; Pseudomonas aeruginosa; Transepithelial electrical resistance (TEER); Tuberculosis

Year:  2021        PMID: 33095300     DOI: 10.1007/164_2020_366

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  103 in total

1.  Nicotine exposure induces bronchial epithelial cell apoptosis and senescence via ROS mediated autophagy-impairment.

Authors:  Manish Bodas; Colin Van Westphal; Rhett Carpenter-Thompson; Dillip K Mohanty; Neeraj Vij
Journal:  Free Radic Biol Med       Date:  2016-07-06       Impact factor: 7.376

Review 2.  Mucus as a barrier to drug delivery – understanding and mimicking the barrier properties.

Authors:  Marie Boegh; Hanne Mørck Nielsen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2014-12-23       Impact factor: 4.080

Review 3.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

4.  Activation of somatostatin receptors attenuates pulmonary fibrosis.

Authors:  R Borie; A Fabre; F Prost; J Marchal-Somme; R Lebtahi; S Marchand-Adam; M Aubier; P Soler; B Crestani
Journal:  Thorax       Date:  2007-10-19       Impact factor: 9.139

5.  In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.

Authors:  Gregory G Anderson; Sophie Moreau-Marquis; Bruce A Stanton; George A O'Toole
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

6.  Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments.

Authors:  P Artursson; A L Ungell; J E Löfroth
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

Review 7.  Pseudomonas aeruginosa biofilms: mechanisms of immune evasion.

Authors:  Maria Alhede; Thomas Bjarnsholt; Michael Givskov; Morten Alhede
Journal:  Adv Appl Microbiol       Date:  2014       Impact factor: 5.086

Review 8.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

Review 9.  In vitro and ex vivo models of human asthma.

Authors:  Cornelia Blume; Donna E Davies
Journal:  Eur J Pharm Biopharm       Date:  2013-01-09       Impact factor: 5.571

Review 10.  Dormancy models for Mycobacterium tuberculosis: A minireview.

Authors:  Amani M Alnimr
Journal:  Braz J Microbiol       Date:  2015-07-01       Impact factor: 2.476

View more
  2 in total

Review 1.  Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models.

Authors:  Luigino Calzetta; Elena Pistocchini; Beatrice Ludovica Ritondo; Francesco Cavalli; Francesca Camardelli; Paola Rogliani
Journal:  Heliyon       Date:  2022-06-22

Review 2.  A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.

Authors:  Siqin He; Jiajia Gui; Kun Xiong; Meiwan Chen; Huile Gao; Yao Fu
Journal:  J Nanobiotechnology       Date:  2022-03-03       Impact factor: 10.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.